Effective enrichment exploits differences between tumor cells and normal blood cells, such as differential expression of tumor-associated cell surface proteins (e.g., EpCAM, mucin-1, HER2, or epithelial growth factor receptor (EGFR)) or distinct physical properties (e.g., larger size or reduced deformability) of tumor cells [14]. This evidence concerns the gene EGFR and neoplasm.